<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">BMC Psychiatry</journal-id><journal-title-group><journal-title>BMC Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1471-244X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25064681</article-id><article-id pub-id-type="pmc">4149262</article-id><article-id pub-id-type="publisher-id">212</article-id><article-id pub-id-type="doi">10.1186/s12888-014-0212-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhanchou</given-names></name><address><email>zzcd@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Zhai</surname><given-names>Jinguo</given-names></name><address><email>zhaijinguo002@126.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Qinling</given-names></name><address><email>qinlingwei001@163.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Qi</surname><given-names>Jingfeng</given-names></name><address><email>bingquan1234@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Guo</surname><given-names>Xiaofeng</given-names></name><address><email>xfguocsu@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhao</surname><given-names>Jingping</given-names></name><address><email>fengcsu@yahoo.com.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Institute of Mental Health, the Second Xiangya Hospital, Central South University, Key Laboratory of Psychiatry and Mental Health of Hunan Province, National Technology Institute of Psychiatry, No. 139 Renmin Middle Road, Changsha, 410011 China </aff><aff id="Aff2"><label/>Jining Medical College, Jining, China </aff><aff id="Aff3"><label/>Department of Psychiatry, 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>212</elocation-id><history><date date-type="received"><day>12</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>18</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Zhang et al., licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>A combination of psychosocial interventions and medications has been highly recommended as a successful treatment package for schizophrenia. Its cost-effectiveness has not been fully explored yet. The aim of the present analysis was to evaluate the cost-effectiveness of antipsychotics combined with psychosocial treatment and treatment as usual for patients with early-stage schizophrenia.</p></sec><sec><title>Method</title><p>Patients with schizophrenia (N&#x02009;=&#x02009;1, 268) were assigned to the combination of medication and psychosocial intervention or treatment as usual for up to 12&#x000a0;months. Cost analysis included direct medical costs, direct nonmedical costs and indirect costs. Quality-adjusted life year (QALY) ratings were assessed with Short- Form 6D.</p></sec><sec><title>Results</title><p>Average monthly psychosocial intervention costs for combined treatment were higher than treatment as usual (p&#x02009;=&#x02009;0.005), but no significant differences were found in direct costs, indirect costs, and total costs between two groups (all p-values&#x02009;&#x02265;&#x02009;0.556). Combined treatment was associated with significant higher QALY ratings than treatment as usual (p&#x02009;=&#x02009;0.039). Compared with treatment as usual, combined treatment resulted in a gain of 0.031 QALY ratings at an additional cost of US$ 56.4, yielding an incremental cost-effectiveness ratio of US$ 1819.4 per QALY gained.</p></sec><sec><title>Conclusions</title><p>Despite some limitations, our results supported that medication combined with psychosocial treatment was more cost-effective than treatment as usual for patients with early-stage schizophrenia.</p></sec><sec><title>Trial registration</title><p>clinicaltrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00654576?term=%2FNCT00654576&#x00026;rank=1">NCT00654576</ext-link></p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12888-014-0212-0) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Schizophrenia</kwd><kwd>Cost-effectiveness</kwd><kwd>Psychosocial intervention</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Schizophrenia is a severe and chronic illness as well as one of the most expensive illnesses to treat [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>], which has a significant impact on individuals, families and societies in terms of both health and economic loss. Schizophrenia is also among the 15 leading causes of disability and the top 10 leading causes of years lost due to disability [<xref ref-type="bibr" rid="CR3">3</xref>]. In China, there are about 10 million patients suffering from schizophrenia, and it is estimated that the annual economic cost of schizophrenia exceeds 1 billion RMB [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>Although antipsychotic medications are the mainstay of the treatment for schizophrenia, patients with schizophrenia benefit more from the combined use of antipsychotic drugs and psychosocial treatment than pharmacotherapy alone in delaying or preventing relapse or reducing hospital days [<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>]. Symptomatic relapse or readmission in schizophrenia is both distressing and costly. It can devastate the lives not only of patients, but also of their families [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Most economic evidence in this area focuses on the cost-effectiveness of medications and different ways of organizing mental health care [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>], and there is still little economic evidence on psychosocial intervention [<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref>]. In a previous article, we reported a 1-year randomized clinical trial that examined the effect of medication combined with psychosocial intervention vs medication treatment alone on outcomes of patients with early stage schizophrenia [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>The current article presents resulted on measures of health care costs and health related quality of life. The primary outcomes were total health costs and quality-adjusted life year (QALY) ratings. Based on a randomized controlled trial, the present study sought to examine whether medication combined psychosocial intervention represents a more cost-effective intervention than treatment as usual for patients with early stage schizophrenia.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>The trial was a multicenter, randomized, and controlled study conducted between January 2005 and October 2007 at 10 clinical sites in China. The background, rationale, and methods of the Early-stage Schizophrenia Outcome Study (ESOS) have been presented in detail previously [<xref ref-type="bibr" rid="CR15">15</xref>]. This study was approved by the institutional review board at <italic>the Second Xiangya Hospital, Chongqing Mental Health Center, Psychiatric Hospital of Jiangxi Province, West China Hospital, Mental Hospital of Henan Province, Beijing Anding Hospital, Shanghai Mental Health Center, Guangzhou Brain Hospital, Hunan Brain Hospital, and Nanjing Brain Hospital.</italic> Written informed consent was obtained from the patients or their legal guardians. Additional files <xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM2" ref-type="media">2</xref> comprise the the full trial protocol and consort statement extension for cluster randomized controlled trials respectively.</p><p>Participants were randomly assigned to receive the combination of medication and psychosocial treatment or treatment as usual (medication treatment and brief intervention) and were monitored for up to 12 months or until medication treatment was discontinued for any reason after baseline assessment. Group assignment was based on a 1:1 randomization scheme balanced by sites and medication prescribed by independent investigator according to a computer generated randomization list.</p></sec><sec id="Sec4"><title>Participants</title><p>Study participants were enrolled from outpatient psychiatric clinics and under maintenance treatment. Inclusion criteria in this study were: (1) age 18 to 50&#x000a0;years old; (2) met DSM-IV diagnostic criteria for schizophrenia or schizophreniform disorder, as determined by the Structured Clinical Interview for DSM-IV Axis I Disorders&#x02013;Clinician Version administered by study investigators[<xref ref-type="bibr" rid="CR16">16</xref>]; (3) length of illness&#x02009;&#x02264;&#x02009;5&#x000a0;years; (4) stable clinical condition (Positive and Negative Syndrome Scale PANSS, [<xref ref-type="bibr" rid="CR17">17</xref>] total scores &#x02264;60); (5) treated with one of the following 7 oral antipsychotics: chlorpromazine, sulpiride, clozapine, risperidone, olanzapine, quetiapine or aripiprazole. Patients were excluded if they were: (1) prescribed two or more antipsychotics or long-acting injectable antipsychotics; (2) participating in other therapy programs; (3) pregnant or breastfeeding; or (4) having serious and unstable medical condition.</p></sec><sec id="Sec5"><title>Intervention</title><p>All patients continued taking the original antipsychotic during the 12-month follow-up period. If a patient&#x02019;s medication was stopped or switched, patients were classified as discontinued and terminated from the study.</p><p>The psychosocial intervention was reported in detail elsewhere [<xref ref-type="bibr" rid="CR15">15</xref>]. In brief, patients who were assigned to the combined treatment group received medication treatment and were enrolled in a psychosocial intervention program. The psychosocial intervention included 4 evidence-based practices: psychoeducation, family intervention, skills training, and cognitive behavior therapy was conducted monthly for 12&#x000a0;months. Participants received the 4 interventions on the same day, for a total of 48 one-hour sessions. A lunch break and 2 half-hour breaks were provided to maintain engagement and attention. Therapists who had at least 2&#x000a0;years of clinical experience after earning an MD or PhD or at least 5&#x000a0;years of experience after earning a masters degree in clinical psychology delivered the psychosocial intervention.</p><p>The brief intervention included case management with antipsychotic medication and supportive interventions, which were provided monthly for 12&#x000a0;months.</p></sec><sec id="Sec6"><title>Measuring service use and costs</title><p>Costs estimates included direct medical costs, direct nonmedical costs, and indirect nonmedical costs. Direct medical costs consisted of intervention costs such as medication tests, therapy and so on, and uptake of health care services, including costs of medication. Service use was documented through a questionnaire completed by the caregiver at the end of every month during the study. Costs were calculated in US dollar ($) for the reference year 2005 in China.</p><p>The costs of psychosocial interventions consisted of start-up costs (development and training) and ongoing costs (services, supplies, travel and salary). We assumed that the psychosocial intervention protocol would be prepared by 2 specialists for 120&#x000a0;hours each and a training program would be conducted for 40 clinicians from all 10 psychiatric hospitals. The intervention program would consist of 42-hour sessions by two therapists [<xref ref-type="bibr" rid="CR15">15</xref>]. We assumed that each session would have 12 participants (6 patients and 6 family carers). The unit cost for each medical procedure was calculated from the price system database built by the National Development and Reform Commission of China [<xref ref-type="bibr" rid="CR18">18</xref>]. Direct nonmedical costs consisted of costs for traveling and parking. These costs were valued at US $ 0.1 per kilometer and US $ 0.5 per hour parking time.</p><p>Indirect nonmedical costs arise when production losses occur due to illness. Production losses can occur under 3 conditions. Patients were absent from paid work due to sick leave (work loss days), or they were ill but continue to work with reduced efficiency (work cutback days), or caregivers were absent from paid work due to take care of patients.</p><p>Cost-effectiveness analysis requires a single measure of health related quality of life that reflects both health gains and health losses. Participants were asked to complete Medical Outcome Study Short-Form 36-item questionnaire (SF-36) [<xref ref-type="bibr" rid="CR19">19</xref>] at baseline, 6&#x000a0;months, and 12&#x000a0;months. The utility scores of the SF-6D derived from responses to eleven questions on the SF-36 questionnaire are used to calculate the QALYs gained during the follow-up period by weighing the length of time spent in a particular health condition by the utility. The SF-6D has 6 dimensions (physical functioning, role limitations, social functioning, pain, mental health and vitality) which have from 4 to 6 levels of severity [<xref ref-type="bibr" rid="CR20">20</xref>]. The SF-6D scoring algorithm has been validated and established for the adult Chinese population in Hong Kong in previous studies [<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref>]. The general population mean SF-6D preference value is 0.787, which was estimated from the SF-36 data of a general population survey of 2410 adult Chinese in Hong Kong in 1998 [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>Other outcomes further assessed treatment effectiveness by measuring rates of treatment discontinuation, symptom severity (PANSS) [<xref ref-type="bibr" rid="CR17">17</xref>] and global severity of illness (Clinical Global Impressions Scale) [<xref ref-type="bibr" rid="CR24">24</xref>]. The social functioning and family burden were rated by the Global Assessment Scale (GAS) [<xref ref-type="bibr" rid="CR25">25</xref>] and Family Burden Scale (FBS) [<xref ref-type="bibr" rid="CR26">26</xref>], respectively. Agreement among the raters was high for the PANSS, CGI and GAS (Pearson correlation coefficient, 0.78-0.86) at baseline and every 6&#x000a0;months. All raters were kept blind for patient's treatment condition.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>All analyses were conducted with the Statistical Package for Social Sciences, version 15.0 (SPSS Inc, Chicago, Illinois). Baseline characteristics were compared between the two groups by analysis of variance, Pearson&#x02019;s chi-square test, or Fisher&#x02019;s exact test, as appropriate. Average monthly costs were compared between the groups with use of a mixed model including the same fixed covariates as for the time to discontinuation, plus baseline value, time, the interaction between treatment and time. Time was classified into months (baseline, 3, 6, 9, and 12&#x000a0;months). All statistical tests were two-tailed.</p><p>In the cost-effectiveness analysis, the average benefit in terms of Quality adjusted life year (QALY) gained and the average cost was calculated for each treatment. The average cost-effectiveness ratio (CER) of each treatment was obtained. We measured the incremental cost-effectiveness ratio (ICER), defined as extra cost per QALY gained [<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR27">27</xref>] with the combined medication and psychosocial intervention (Combined treatment) and treatment as usual (TAU).<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{ICER} = \left({\mathrm{Cost}}_{\mathrm{Combined}\ \mathrm{treatment}}-{\mathrm{Cost}}_{\mathrm{TAU}}\right)/\left({\mathrm{Effect}}_{\mathrm{Combined}\ \mathrm{treatment}}-{\mathrm{Effect}}_{\mathrm{TAU}}\right) $$\end{document}</tex-math><mml:math id="M2"><mml:mi mathvariant="normal">ICER</mml:mi><mml:mspace width="0.25em"/><mml:mo>=</mml:mo><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">Cost</mml:mi><mml:mrow><mml:mi mathvariant="normal">Combined</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">treatment</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">Cost</mml:mi><mml:mi mathvariant="normal">TAU</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mo stretchy="true">/</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">Effect</mml:mi><mml:mrow><mml:mi mathvariant="normal">Combined</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">treatment</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">Effect</mml:mi><mml:mi mathvariant="normal">TAU</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="12888_2014_212_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p><p>A strategy was considered as cost-effective versus treatment as usual when ICERs were below the cost-utility threshold acceptable in China. We used 3&#x02009;&#x000d7;&#x02009;the per capita GDP of China in 2005 (US $ 5,100)/QALY as the threshold according to WHO recommendation [<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec8"><title>Sensitivity analysis</title><p>In this study, one-way deterministic analysis was carried out to test the model&#x02019;s robustness. One-way deterministic analysis included modifications of the following inputs: the number of subjects per workshop that was varied from 5 to 3, and the clinical effect and the cost of per workshop that were varied by&#x02009;&#x000b1;&#x02009;20%. The psychosocial intervention workshops were designed to be delivered to 6 patients, and the total cost of providing the intervention is the same even if fewer subjects attend. The per-person cost of the intervention therefore varies depending on the number of subjects per workshop. Assuming that the effectiveness of the intervention was the same, we decreased the number of subjects per workshop in sensitivity analysis.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Participants</title><p>Altogether, 1268 participants entered the study, 633 were assigned to receive antipsychotics combined with psychosocial intervention (of whom 29 refused the psychosocial intervention) and 635 to receive treatment as usual. Baseline utilization data were not available for 55, leaving 1184 patients for analysis (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Flowchart of participation in the study.</bold>
</p></caption><graphic xlink:href="12888_2014_212_Fig1_HTML" id="MO1"/></fig></p><p>There were no significant differences between study groups with respect to baseline demographic and clinical characteristics (all p-values&#x02009;&#x02265;&#x02009;0.057). The mean age was 26&#x000a0;years, and 55 percent of the patients were male (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Patient characteristics at the time of random assignment by initial treatment</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Characters</bold>
</th><th>
<bold>Combined treatment (n&#x02009;=&#x02009;580)</bold>
</th><th>
<bold>Treatment as usual (n&#x02009;=&#x02009;604)</bold>
</th><th>
<bold>F/</bold>
<bold><italic>&#x003c7;</italic></bold>
<sup><bold>2</bold></sup>
</th><th>
<bold>p</bold>
</th></tr></thead><tbody><tr valign="top"><td>Age, y</td><td>26.1(7.6)</td><td>26.3(8.0)</td><td>0.237</td><td>0.626</td></tr><tr valign="top"><td>Male No.(%)</td><td>312(53.8)</td><td>336(55.6)</td><td>0.403</td><td>0.526</td></tr><tr valign="top"><td>Marital status No.(%)</td><td/><td/><td>3.113</td><td>0.211</td></tr><tr valign="top"><td>Married</td><td>143(24.7)</td><td>164(27.2)</td><td/><td/></tr><tr valign="top"><td>Previously married</td><td>37(6.4)</td><td>26(4.3)</td><td/><td/></tr><tr valign="top"><td>Never married</td><td>400(69.0)</td><td>414(68.5)</td><td/><td/></tr><tr valign="top"><td>Education, y</td><td>12.2(2.9)</td><td>11.9(2.9)</td><td>2.564</td><td>0.110</td></tr><tr valign="top"><td>Duration of schizophrenia, mo</td><td>22.5(20.0)</td><td>24.7(21.0)</td><td>3.462</td><td>0.063</td></tr><tr valign="top"><td>PANSS total score</td><td>44.6(13.5)</td><td>45.3(13.9)</td><td>0.799</td><td>0.372</td></tr><tr valign="top"><td>CGI severity score</td><td>2.5(1.2)</td><td>2.6(1.2)</td><td>0.849</td><td>0.357</td></tr><tr valign="top"><td>GAS total score</td><td>74.2(11.8)</td><td>74.2(11.9)</td><td>0.000</td><td>0.984</td></tr><tr valign="top"><td>FBS total score</td><td>12.3(7.6)</td><td>12.6(7.9)</td><td>0.468</td><td>0.494</td></tr><tr valign="top"><td>SF-36</td><td/><td/><td/><td/></tr><tr valign="top"><td>PCS</td><td>49.6(7.4)</td><td>51.0(16.6)</td><td>3.621</td><td>0.057</td></tr><tr valign="top"><td>MCS</td><td>50.3(10.5)</td><td>49.4(12.5)</td><td>1.617</td><td>0.204</td></tr></tbody></table><table-wrap-foot><p>PANSS&#x02009;=&#x02009;Positive and Negative Syndrome Scale; CGI&#x02009;=&#x02009;Clinical Global Impressions Scale; GAS&#x02009;=&#x02009;Global Assessment Scale; FBS&#x02009;=&#x02009;family burden scale of diseases; SF-36&#x02009;=&#x02009;the 36-Item Short Form Health Survey; PCS&#x02009;=&#x02009;the Physical Component Score; MCS&#x02009;=&#x02009;the Mental Component Score.</p></table-wrap-foot></table-wrap></p><p>In the intention-to-treat analysis using all available follow-up data, 62.8% of patients completed 1-year evaluation, with significant differences in the proportion of participants in two treatments groups (70.0% for combined treatment group and 56.0% for treatment as usual group, <italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;24.975, df&#x02009;=&#x02009;1, p&#x02009;&#x0003c;&#x02009;0.001).</p></sec><sec id="Sec11"><title>Costs</title><p>Average monthly costs by treatment groups were showed in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The majority costs were attributable to the direct costs. Average monthly psychosocial intervention costs were higher for combined treatment than treatment as usual (p&#x02009;=&#x02009;0.005), but no significant differences were found in direct costs, indirect costs, and total costs between two groups (all p-values&#x02009;&#x02265;&#x02009;0.556).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Average monthly costs by treatment group over 12 months</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Type of cost (US $)</bold>
</th><th>
<bold>Combined treatment (n&#x02009;=&#x02009;580)</bold>
</th><th>
<bold>Treatment as usual (n&#x02009;=&#x02009;604)</bold>
</th><th>
<bold>F</bold>
</th><th>
<bold>p</bold>
</th></tr></thead><tbody><tr valign="top"><td>Direct medical costs</td><td>112.2(8.9)</td><td>107.5(9.2)</td><td>0.167</td><td>0.918</td></tr><tr valign="top"><td>Medication costs</td><td>77.7(7.9)</td><td>79.2(8.1)</td><td>0.014</td><td>0.998</td></tr><tr valign="top"><td>Intervention costs</td><td>6.9(1.7)</td><td>1.8(1.3)</td><td>7.837</td><td>0.005</td></tr><tr valign="top"><td>Health care use costs<sup>a</sup>
</td><td>25.7(3.9)</td><td>25.4(3.8)</td><td>0.141</td><td>0.707</td></tr><tr valign="top"><td>Direct nonmedical costs</td><td>7.4(1.3)</td><td>6.5(1.4)</td><td>0.226</td><td>0.878</td></tr><tr valign="top"><td>Indirect costs</td><td>94.7(14.0)</td><td>97.1(14.4)</td><td>0.007</td><td>0.999</td></tr><tr valign="top"><td>Total costs</td><td>213.3(18.6)</td><td>213.2(19.2)</td><td>0.116</td><td>0.951</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Excluded intervention costs.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Effectiveness</title><p>As shown in Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, significant improvement in QALY ratings was found from baseline to 12&#x000a0;months. Combined treatment was associated with higher QALY ratings than treatment as usual (p&#x02009;=&#x02009;0.039). Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> reported mixed model-adjusted means of the effectiveness measured by treatment groups across months 6 and 12. Differences between two treatment groups were also observed in FBS total scores and SF-36 the Physical Component Score (PCS) and the Mental Component Score (MCS) scores (all p-values&#x02009;&#x02264;&#x02009;0.042).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Average monthly quality-adjusted life year rating.</bold>
</p></caption><graphic xlink:href="12888_2014_212_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Comparison of effectiveness by Treatment Groups (adjusted means across all points based on mixed models)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Effectiveness measure</bold>
</th><th>
<bold>Combined treatment (n&#x02009;=&#x02009;580)</bold>
</th><th>
<bold>Treatment as usual (n&#x02009;=&#x02009;604)</bold>
</th><th>
<bold>F</bold>
</th><th>
<bold>p</bold>
</th></tr></thead><tbody><tr valign="top"><td>QALYs</td><td>0.676(0.004)</td><td>0.658(0.004)</td><td>3.259</td><td>0.039</td></tr><tr valign="top"><td>SF-36</td><td/><td/><td/><td/></tr><tr valign="top"><td>PCS</td><td>50.6(0.3)</td><td>50.3(0.2)</td><td>4.650</td><td>0.010</td></tr><tr valign="top"><td>MCS</td><td>51.5(0.3)</td><td>49.1(0.3)</td><td>3.643</td><td>0.026</td></tr><tr valign="top"><td>FBS</td><td>8.6(0.2)</td><td>10.1(0.2)</td><td>2.484</td><td>0.042</td></tr><tr valign="top"><td>PANSS total scores</td><td>38.5(0.2)</td><td>40.0(0.2)</td><td>0.406</td><td>0.810</td></tr></tbody></table><table-wrap-foot><p>QALYs&#x02009;=&#x02009;quality-adjusted life-years; PANSS&#x02009;=&#x02009;Positive and Negative Syndrome Scale; SF-36&#x02009;=&#x02009;the 36-Item Short Form Health Survey; PCS&#x02009;=&#x02009;the Physical Component Score; MCS&#x02009;=&#x02009;the Mental Component Score; FBS&#x02009;=&#x02009;family burden scale of diseases.</p></table-wrap-foot></table-wrap></p><p>Compared with treatment as usual, combined treatment resulted in a gain of 0.031 QALYs at an additional cost of US$ 56.4, yielding an incremental cost-effectiveness ratio of US$ 1819.4 per QALY gained. Considering the common threshold accepted in China (US$ 5,100 per QALY gained), combined treatment could be considered a cost-effective option compared to treatment as usual.</p><p>At the end of the study, 14.6 percent of patients in the combined treatment group and 22.5 percent of patients in treatment as usual group had relapsed (<italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;12.899, df&#x02009;=&#x02009;1, p&#x02009;&#x0003c;&#x02009;0.001); readmission occurred in 6.5% of patients in the combined treatment group and 11.2% of patients in treatment as usual group (<italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;8.540, df&#x02009;=&#x02009;1, p&#x02009;=&#x02009;0.003).</p></sec><sec id="Sec13"><title>Sensitivity analyses</title><p>Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> showed the details of the sensitivity analysis performed. The combined treatment was always a dominant strategy over treatment as usual.<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Sensitivity analysis</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Parameter</bold>
</th><th>
<bold>Average CER (US $/QALY)</bold>
</th><th>
<bold>ICER</bold>
</th></tr></thead><tbody><tr valign="top"><td>Base case (BC)</td><td>14960</td><td>1819.4</td></tr><tr valign="top"><td>Patients attendance per workshop</td><td/><td/></tr><tr valign="top"><td>5 cases (&#x02212;16% BC)</td><td>15144</td><td>2354.8</td></tr><tr valign="top"><td>4 cases (&#x02212;33% BC)</td><td>15422</td><td>3161.3</td></tr><tr valign="top"><td>3 cases (&#x02212;50% BC)</td><td>15882</td><td>4496.8</td></tr><tr valign="top"><td>Cost per workshop</td><td/><td/></tr><tr valign="top"><td>+20% BC</td><td>15093</td><td>2206.5</td></tr><tr valign="top"><td>- 20% BC</td><td>14827</td><td>1432.3</td></tr><tr valign="top"><td>Clinical effect</td><td/><td/></tr><tr valign="top"><td>+20% BC</td><td>12467</td><td>1151.0</td></tr><tr valign="top"><td>- 20% BC</td><td>18700</td><td>4338.5</td></tr></tbody></table><table-wrap-foot><p>QALYs&#x02009;=&#x02009;quality-adjusted life-years; CER&#x02009;=&#x02009;incremental cost effectiveness ratio; ICER&#x02009;=&#x02009;incremental cost effectiveness ratio.</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>Schizophrenia is a very serious costly mental illness [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>]. In this relatively large clinical trial of medication combined psychosocial intervention for outpatients with early-stage schizophrenia, we found that combined treatment group had slightly higher QALYs than treatment as usual group, but there were no statistically significant differences in medication costs or total health costs. These results were consistent with previous reports [<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref>] in which patients were treated with medication and psychosocial intervention substantially increased health gain with lower medical cost. The differences between two groups in FBS total scores and SF-36 PCS and MCS scores in present study further supports previous studies [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>These results extend the efficacy and safety outcomes analysis from the first report of the ESOS study, which showed that patients with early-stage schizophrenia receiving combined medication and psychosocial intervention had a lower rate of treatment discontinuation or change, a lower risk of relapse, and improved insight, quality of life, and social functioning compared with those receiving treatment as usual [<xref ref-type="bibr" rid="CR15">15</xref>]. Average monthly psychosocial intervention costs were higher for combined treatment than treatment as usual, but no significant differences were found in direct costs, indirect costs, and total costs Individual payments play a huge role in the current Chinese health care system. Patients with schizophrenia have to stay at home to take medicine except for hospitalization in mental hospital or seeing doctor in out-patient in China [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>Family caregivers experience significant burden in taking care of their patients with schizophrenia, and family members may influence their relative's adherence with medication and other treatment regimens [<xref ref-type="bibr" rid="CR30">30</xref>]. In our study, the family caregivers of patients assigned to combined treatment reported less burden overall over 12&#x000a0;months than the caregivers of patients assigned to medication only treatment, suggesting that combined treatment may decrease the family burden.</p><p>This study has several limitations. First, this was a 12-month trial; a longer-term randomized clinical trial would contribute substantially to understanding cost-effectiveness of psychosocial intervention on schizophrenia. Second, data loss from attrition was considerable. More patients in medication group dropped out for medication discontinuation or relapse than combined treatment group. Partial compliance with antipsychotic medication is associated with an increased risk of inpatient hospitalization. As we all know, relapse and rehospitalization contribute significantly to the economic burden of schizophrenia [<xref ref-type="bibr" rid="CR9">9</xref>]. However, we did not continue to collect any information when medication discontinuation or clinical relapse happened, also did not measure costs associated with relapse. This may be the important reason why combined psychosocial intervention was substantially more effective (using rates of discontinuation for any cause as the measure of effectiveness), but slightly higher QALYs than medication treatment alone in present study. Third, we used self-report for most of the measures. Self-report can be vulnerable to recall bias. The self-report of medication and care products for example, is often underestimated [<xref ref-type="bibr" rid="CR31">31</xref>]. Last, this study recruited only patients with early-stage schizophrenia. Further prospective data monitoring studies are needed to evaluate chronic schizophrenic patient costs.</p></sec><sec id="Sec15" sec-type="conclusion"><title>Conclusion</title><p>A combination of psychosocial interventions and medications has been highly recommended as a successful treatment package for schizophrenia [<xref ref-type="bibr" rid="CR6">6</xref>]. Despite there were some limitations, present results confirmed that combined intervention package was more cost-effective than treatment as usual in early stage schizophrenia. Future research is needed to evaluate the longer-term effects on patient outcomes and consider broader measures of health care resource utilization.</p></sec></body><back><app-group><app id="App1"><sec id="Sec16"><title>Additional files</title><p><media position="anchor" xlink:href="12888_2014_212_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1:</label><caption><p>
<bold>Protocol.</bold> Antipsychotic combination with psychosocial intervention on the early-stage schizopherenia outcome study.</p></caption></media><media position="anchor" xlink:href="12888_2014_212_MOESM2_ESM.doc" id="MOESM2"><label>Additional file 2:</label><caption><p>
<bold>The consort statement for cluster randomised controlled trials.</bold>
</p></caption></media></p></sec></app></app-group><fn-group><fn><p><bold>Competing interests</bold></p><p>All authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>ZC, GF carried out the study, participated in the analysis and interpretation of data and wrote the manuscript. ZG, WL, and QF were involved in carrying out the study and revising the manuscript. ZP conceived of the study and participated in its design and coordination and obtained the funding. All authors contributed to the article and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We wish to thank all the investigators of Early-stage Schizophrenia Outcome Study (ESOS) who enrolled patients and collected data: Dr. B. Wang, Dr. B. Hu, Dr. X. Sun, Dr. L. Lv, Dr. C. Wang, Dr. Z. Lu, Dr. C. Ma, Dr. T. Guo, and Dr. S. Xie. We are also very grateful to Haijun Deng from School of Public Health, Central South University for assistance in revising our manuscript.</p><p>This study was supported by the National Key Technologies R&#x00026;D Program in the 10th 5-year-plan of China (Grant No. 2004BA720A22); and the National R&#x00026;D Special Fund for Health Profession (Grant No. 201002003).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>EQ</given-names></name><name><surname>Birnbaum</surname><given-names>HG</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Ball</surname><given-names>DE</given-names></name><name><surname>Kessler</surname><given-names>RC</given-names></name><name><surname>Moulis</surname><given-names>M</given-names></name><name><surname>Aggarwal</surname><given-names>J</given-names></name></person-group><article-title>The economic burden of schizophrenia in the United States in 2002</article-title><source>J Clin Psychiatry</source><year>2005</year><volume>66</volume><fpage>1122</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.4088/JCP.v66n0906</pub-id><pub-id pub-id-type="pmid">16187769</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knapp</surname><given-names>M</given-names></name><name><surname>Mangalore</surname><given-names>R</given-names></name><name><surname>Simon</surname><given-names>J</given-names></name></person-group><article-title>The global costs of schizophrenia</article-title><source>Schizophr Bull</source><year>2004</year><volume>30</volume><fpage>279</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.schbul.a007078</pub-id><pub-id pub-id-type="pmid">15279046</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>The Global Burden of Disease: 2004 Update</source><year>2008</year><publisher-loc>Geneva</publisher-loc><publisher-name>WHO</publisher-name></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JF</given-names></name><name><surname>Lambert</surname><given-names>CE</given-names></name><name><surname>Lambert</surname><given-names>VA</given-names></name></person-group><article-title>Predictors of family caregivers&#x02019; burden and quality of life when providing care for a family member with schizophrenia in the People&#x02019;s Republic of China</article-title><source>Nurs Health Sci</source><year>2007</year><volume>9</volume><fpage>192</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1111/j.1442-2018.2007.00327.x</pub-id><pub-id pub-id-type="pmid">17688477</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>ML</given-names></name></person-group><article-title>The economic cost of schizophrenia [in Chinese]</article-title><source>Chin Health Econ Mag</source><year>2003</year><volume>22</volume><fpage>28</fpage><lpage>29</lpage></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>TL</given-names></name><name><surname>Leeuwenkamp</surname><given-names>OR</given-names></name></person-group><article-title>Adjunctive psychosocial therapies for the treatment of schizophrenia</article-title><source>Schizophr Res</source><year>2008</year><volume>100</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2007.12.468</pub-id><pub-id pub-id-type="pmid">18226500</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penn</surname><given-names>DL</given-names></name><name><surname>Waldheter</surname><given-names>EJ</given-names></name><name><surname>Perkins</surname><given-names>DO</given-names></name><name><surname>Mueser</surname><given-names>KT</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name></person-group><article-title>Psychosocial treatment for first-episode psychosis: a research update</article-title><source>Am J Psychiatry</source><year>2005</year><volume>162</volume><fpage>2220</fpage><lpage>2232</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.162.12.2220</pub-id><pub-id pub-id-type="pmid">16330584</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbaum</surname><given-names>B</given-names></name><name><surname>Valbak</surname><given-names>K</given-names></name><name><surname>Harder</surname><given-names>S</given-names></name><name><surname>Knudsen</surname><given-names>P</given-names></name><name><surname>K&#x000f8;ster</surname><given-names>A</given-names></name><name><surname>Lajer</surname><given-names>M</given-names></name><name><surname>Lindhardt</surname><given-names>A</given-names></name><name><surname>Winther</surname><given-names>G</given-names></name><name><surname>Petersen</surname><given-names>L</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>P</given-names></name><name><surname>Nordentoft</surname><given-names>M</given-names></name><name><surname>Andreasen</surname><given-names>AH</given-names></name></person-group><article-title>The Danish National Schizophrenia Project: prospective, comparative longitudinal treatment study of first-episode psychosis</article-title><source>Br J Psychiatry</source><year>2005</year><volume>186</volume><fpage>394</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1192/bjp.186.5.394</pub-id><pub-id pub-id-type="pmid">15863743</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almond</surname><given-names>S</given-names></name><name><surname>Knapp</surname><given-names>M</given-names></name><name><surname>Francois</surname><given-names>C</given-names></name><name><surname>Toumi</surname><given-names>M</given-names></name><name><surname>Brugha</surname><given-names>T</given-names></name></person-group><article-title>Relapse in schizophrenia: costs, clinical outcomes and quality of life</article-title><source>Br J Psychiatry</source><year>2004</year><volume>184</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1192/bjp.184.4.346</pub-id><pub-id pub-id-type="pmid">15056580</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>NC</given-names></name><name><surname>Locklear</surname><given-names>JC</given-names></name><name><surname>Rupnow</surname><given-names>MF</given-names></name><name><surname>Diamond</surname><given-names>RJ</given-names></name></person-group><article-title>Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA</article-title><source>Pharmacoeconomics</source><year>2005</year><volume>23</volume><issue>Suppl 1</issue><fpage>75</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.2165/00019053-200523001-00007</pub-id><pub-id pub-id-type="pmid">16416763</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>PG</given-names></name><name><surname>Scott</surname><given-names>JY</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Rosenheck</surname><given-names>RA</given-names></name><collab>CSP 555 Research Group</collab></person-group><article-title>Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia</article-title><source>J Clin Psychiatry</source><year>2005</year><volume>73</volume><fpage>696</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.4088/JCP.11m07070</pub-id><pub-id pub-id-type="pmid">22697193</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenheck</surname><given-names>RA</given-names></name><name><surname>Leslie</surname><given-names>DL</given-names></name><name><surname>Sindelar</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>EA</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Stroup</surname><given-names>TS</given-names></name><name><surname>McEvoy</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>SM</given-names></name><name><surname>Keefe</surname><given-names>RS</given-names></name><name><surname>Swartz</surname><given-names>M</given-names></name><name><surname>Perkins</surname><given-names>DO</given-names></name><name><surname>Hsiao</surname><given-names>JK</given-names></name><name><surname>Lieberman</surname><given-names>J</given-names></name><collab>CATIE Study Investigators</collab></person-group><article-title>Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia</article-title><source>Am J Psychiatry</source><year>2006</year><volume>163</volume><fpage>2080</fpage><lpage>2089</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.163.12.2080</pub-id><pub-id pub-id-type="pmid">17151158</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Knapp</surname><given-names>M</given-names></name><name><surname>Romeo</surname><given-names>R</given-names></name><name><surname>Reeder</surname><given-names>C</given-names></name><name><surname>Matthiasson</surname><given-names>P</given-names></name><name><surname>Everitt</surname><given-names>B</given-names></name><name><surname>Wykes</surname><given-names>T</given-names></name></person-group><article-title>Cognitive remediation therapy in schizophrenia: cost-effectiveness analysis</article-title><source>Schizophr Res</source><year>2010</year><volume>120</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2009.12.003</pub-id><pub-id pub-id-type="pmid">20056391</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phanthunane</surname><given-names>P</given-names></name><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Whiteford</surname><given-names>H</given-names></name><name><surname>Bertram</surname><given-names>M</given-names></name></person-group><article-title>Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia</article-title><source>Cost Eff Resour Alloc</source><year>2011</year><volume>9</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1478-7547-9-6</pub-id><pub-id pub-id-type="pmid">21569448</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>XF</given-names></name><name><surname>Zhai</surname><given-names>JG</given-names></name><name><surname>Liu</surname><given-names>ZN</given-names></name><name><surname>Fang</surname><given-names>MS</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Xue</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Twamley</surname><given-names>EW</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name></person-group><article-title>Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study</article-title><source>Arch Gen Psychiatry</source><year>2010</year><volume>67</volume><fpage>895</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.105</pub-id><pub-id pub-id-type="pmid">20819983</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Gibbon</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>JBW</given-names></name><name><surname>Benjamin</surname><given-names>LS</given-names></name></person-group><source>Structured Clinical Interview for DSM-IV Axis I Disorders&#x02013;Clinician Version (SCID-CV)</source><year>1997</year><publisher-loc>Washington, DC</publisher-loc><publisher-name>American Psychiatry Press</publisher-name></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>SR</given-names></name><name><surname>Fiszbein</surname><given-names>A</given-names></name><name><surname>Opler</surname><given-names>LA</given-names></name></person-group><article-title>The positive and negative syndrome scale (PANSS) for schizophrenia</article-title><source>Schizophr Bull</source><year>1987</year><volume>13</volume><fpage>261</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1093/schbul/13.2.261</pub-id><pub-id pub-id-type="pmid">3616518</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Tao</surname><given-names>LB</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Nicholl</surname><given-names>MD</given-names></name><name><surname>Dong</surname><given-names>P</given-names></name></person-group><article-title>Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China</article-title><source>Value Health</source><year>2009</year><volume>12</volume><issue>Suppl 3</issue><fpage>66</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4733.2009.00630.x</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCrone</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Knapp</surname><given-names>M</given-names></name><name><surname>Schene</surname><given-names>A</given-names></name><name><surname>Koeter</surname><given-names>M</given-names></name><name><surname>Amaddeo</surname><given-names>F</given-names></name><name><surname>Ruggeri</surname><given-names>M</given-names></name><name><surname>Giessler</surname><given-names>A</given-names></name><name><surname>Puschner</surname><given-names>B</given-names></name><name><surname>Thornicroft</surname><given-names>G</given-names></name></person-group><article-title>A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia</article-title><source>J Ment Health Policy Econ</source><year>2009</year><volume>12</volume><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">19346564</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brazier</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>J</given-names></name><name><surname>Deverill</surname><given-names>M</given-names></name></person-group><article-title>The estimation of a preference-based measure of health from the SF-36</article-title><source>J Health Econ</source><year>2002</year><volume>21</volume><fpage>271</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/S0167-6296(01)00130-8</pub-id><pub-id pub-id-type="pmid">11939242</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGhee</surname><given-names>SM</given-names></name><name><surname>Brazier</surname><given-names>J</given-names></name><name><surname>Lam</surname><given-names>CLK</given-names></name><name><surname>Wong</surname><given-names>LC</given-names></name><name><surname>Chau</surname><given-names>J</given-names></name><name><surname>Cheung</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name></person-group><article-title>Quality-adjusted life years: population-specific measurement of the quality component</article-title><source>Hong Kong Med J</source><year>2011</year><volume>17</volume><issue>Suppl 6</issue><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">22147354</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>CLK</given-names></name><name><surname>Brazier</surname><given-names>J</given-names></name><name><surname>McGhee</surname><given-names>SM</given-names></name></person-group><article-title>Valuation of the SF-6D health states is feasible, acceptable, reliable, and valid in a Chinese population</article-title><source>Value Health</source><year>2008</year><volume>11</volume><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4733.2007.00233.x</pub-id><pub-id pub-id-type="pmid">18380642</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>ETP</given-names></name><name><surname>Lam</surname><given-names>CLK</given-names></name><name><surname>Lo</surname><given-names>YYC</given-names></name><name><surname>Grandek</surname><given-names>B</given-names></name></person-group><article-title>Psychometrics and population norm of the Chinese (HK) SF-36 Health Survey version 2</article-title><source>HK Pract</source><year>2008</year><volume>30</volume><fpage>185</fpage><lpage>198</lpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>W</given-names></name></person-group><source>ECDEU Assessment Manual for Psychopharmacology. Rev ed</source><year>1976</year><publisher-loc>Rockville</publisher-loc><publisher-name>Dept of Health, Education, and Welfare</publisher-name></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endicott</surname><given-names>J</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Fleiss</surname><given-names>JL</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance</article-title><source>Arch Gen Psychiatry</source><year>1976</year><volume>33</volume><fpage>766</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1976.01770060086012</pub-id><pub-id pub-id-type="pmid">938196</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>S</given-names></name><name><surname>Kapur</surname><given-names>RL</given-names></name></person-group><article-title>The burden on the family of a psychiatric patient: development of an interview schedule</article-title><source>Br J Psychiatry</source><year>1981</year><volume>138</volume><fpage>332</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1192/bjp.138.4.332</pub-id><pub-id pub-id-type="pmid">7272637</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoch</surname><given-names>JS</given-names></name><name><surname>Briggs</surname><given-names>A</given-names></name><name><surname>Willan</surname><given-names>A</given-names></name></person-group><article-title>Something old, something new, something borrowed, something blue: a framework for the marriage of health economics and cost effectiveness analysis</article-title><source>Health Econ</source><year>2002</year><volume>11</volume><fpage>415</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1002/hec.678</pub-id><pub-id pub-id-type="pmid">12112491</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chisholm</surname><given-names>D</given-names></name><name><surname>Gureje</surname><given-names>O</given-names></name><name><surname>Saldivia</surname><given-names>S</given-names></name><name><surname>Villal&#x000f3;n Calder&#x000f3;n</surname><given-names>M</given-names></name><name><surname>Wickremasinghe</surname><given-names>R</given-names></name><name><surname>Mendis</surname><given-names>N</given-names></name><name><surname>Ayuso-Mateos</surname><given-names>JL</given-names></name><name><surname>Saxena</surname><given-names>S</given-names></name></person-group><article-title>Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis</article-title><source>Bull World Health Organ</source><year>2008</year><volume>86</volume><fpage>542</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.2471/BLT.07.045377</pub-id><pub-id pub-id-type="pmid">18670667</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name></person-group><article-title>An investigation of economic costs of schizophrenia in two areas of China</article-title><source>Int J Ment Health Syst</source><year>2013</year><volume>15</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/1752-4458-7-26</pub-id><pub-id pub-id-type="pmid">24237846</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlick</surname><given-names>DA</given-names></name><name><surname>Rosenheck</surname><given-names>RA</given-names></name><name><surname>Kaczynski</surname><given-names>R</given-names></name><name><surname>Swartz</surname><given-names>MS</given-names></name><name><surname>Canive</surname><given-names>JM</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name></person-group><article-title>Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial</article-title><source>Schizophr Res</source><year>2010</year><volume>116</volume><fpage>118</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2009.09.026</pub-id><pub-id pub-id-type="pmid">19864114</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Brink</surname><given-names>M</given-names></name><name><surname>van den Hout</surname><given-names>WB</given-names></name><name><surname>Stiggelbout</surname><given-names>AM</given-names></name><name><surname>van de Velde</surname><given-names>CJ</given-names></name><name><surname>Kievit</surname><given-names>J</given-names></name></person-group><article-title>Cost measurement in economic evaluations of health care: whom to ask?</article-title><source>Med Care</source><year>2004</year><volume>42</volume><fpage>740</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1097/01.mlr.0000132351.78009.a1</pub-id><pub-id pub-id-type="pmid">15258475</pub-id></element-citation></ref></ref-list></back></article>